Artelo Biosciences (NASDAQ:ARTL) posted its quarterly earnings results on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.13, Yahoo Finance reports.
Shares of NASDAQ ARTL opened at $1.25 on Tuesday. The business’s 50 day moving average is $1.32 and its two-hundred day moving average is $1.50. Artelo Biosciences has a 52-week low of $0.61 and a 52-week high of $4.42. The firm has a market cap of $4.27 million and a price-to-earnings ratio of -0.78.
In other Artelo Biosciences news, Director Connie Matsui acquired 41,667 shares of the stock in a transaction dated Monday, May 4th. The stock was acquired at an average cost of $1.27 per share, with a total value of $52,917.09. Over the last quarter, insiders purchased 50,034 shares of company stock valued at $63,333. 12.78% of the stock is currently owned by company insiders.
ARTL has been the subject of a number of research reports. Maxim Group cut Artelo Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, May 13th. ValuEngine upgraded Artelo Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd.
About Artelo Biosciences
Artelo Biosciences, Inc, an ethical biopharmaceutical company, focuses on developing, licensing, and commercializing cannabinoid therapeutic treatments. Its products pipeline includes ART12.11, a cannabidiol composition for the treatment of inflammatory bowel disease, stroke, and rare/orphan diseases; ART26.12, an endocannabinoid transport protein (FABP5) inhibitor for the treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain; and ART27.13 for the treatment of cancer and cachexia.
Further Reading: Holder of Record
Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.